|
1
|
Roehlen N, Crouchet E and Baumert TF:
Liver fibrosis: Mechanistic concepts and therapeutic perspectives.
Cells. 9:8752020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee YA, Wallace MC and Friedman SL:
Pathobiology of liver fibrosis: A translational success story. Gut.
64:830–841. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Konyn P, Ahmed A and Kim D: Current
epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol
Hepatol. 15:1295–1307. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harrison SA, Goodman Z, Jabbar A,
Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM,
Kayali Z, Zivony A, et al: A randomized, placebo-controlled trial
of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol.
72:816–827. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kimura K, Ikoma A, Shibakawa M, Shimoda S,
Harada K, Saio M, Imamura J, Osawa Y, Kimura M, Nishikawa K, et al:
Safety, Tolerability, and preliminary efficacy of the anti-fibrotic
small molecule PRI-724, a CBP/β-catenin inhibitor, in patients with
hepatitis C virus-related cirrhosis: A single-center, open-label,
dose escalation phase 1 trial. EBioMedicine. 23:79–87. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muir AJ, Levy C, Janssen HLA, Montano-Loza
AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ,
et al: Simtuzumab for primary sclerosing cholangitis: Phase 2 study
results with insights on the natural history of the disease.
Hepatology. 69:684–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman SL, Ratziu V, Harrison SA,
Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G,
Kowdley KV, Craxi A, et al: A randomized, placebo-controlled trial
of cenicriviroc for treatment of nonalcoholic steatohepatitis with
fibrosis. Hepatology. 67:1754–1767. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Friedman SL: Hepatic fibrosis: Emerging
therapies. Dig Dis. 33:504–507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Altamirano-Barrera A, Barranco-Fragoso B
and Méndez-Sánchez N: Management strategies for liver fibrosis. Ann
Hepatol. 16:48–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Higashi T, Friedman SL and Hoshida Y:
Hepatic stellate cells as key target in liver fibrosis. Adv Drug
Del Rev. 121:27–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Coll M, Perea L, Boon R, Leite SB,
Vallverdú J, Mannaerts I, Smout A, El Taghdouini A, Blaya D,
Rodrigo-Torres D, et al: Generation of hepatic stellate cells from
human pluripotent stem cells enables in vitro modeling of liver
fibrosis. Cell Stem Cell. 23:101–113.e107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuchida T and Friedman SL: Mechanisms of
hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol.
14:397–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fathizadeh H, Hayat SMG, Dao S, Ganbarov
K, Tanomand A, Asgharzadeh M and Kafil HS: Long non-coding RNA
molecules in tuberculosis. Int J Biol Macromol. 156:340–346. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peng H, Wan LY, Liang JJ, Zhang YQ, Ai WB
and Wu JF: The roles of lncRNA in hepatic fibrosis. Cell Biosci.
8:632018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang K, Shi Z, Zhang M, Dong X, Zheng L,
Li G, Han X, Yao Z, Han T and Hong W: Silencing lncRNA Lfar1
alleviates the classical activation and pyoptosis of macrophage in
hepatic fibrosis. Cell Death Dis. 11:1322020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liao J, Zhang Z, Yuan Q, Liu Q, Kuang J,
Fang Y and Hu X: A lncRNA Gpr137b-ps/miR-200a-3p/CXCL14 axis
modulates hepatic stellate cell (HSC) activation. Toxicol Lett.
336:21–31. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gong Z, Tang J, Xiang T, Lin J, Deng C,
Peng Y, Zheng J and Hu G: Genome-wide identification of long
noncoding RNAs in CCl4-induced liver fibrosis via RNA sequencing.
Mol Med Rep. 18:299–307. 2018.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang TH, Huang HY, Hsu JB, Weng SL, Horng
JT and Huang HD: An enhanced computational platform for
investigating the roles of regulatory RNA and for identifying
functional RNA motifs. BMC Bioinformatics. 14 (Suppl 2):S42013.
View Article : Google Scholar
|
|
20
|
Wei S, Wang Q, Zhou H, Qiu J, Li C, Shi C,
Zhou S, Liu R and Lu L: miR-455-3p alleviates hepatic stellate cell
activation and liver fibrosis by suppressing HSF1 expression. Mol
Ther Nucleic Acids. 16:758–769. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seki E and Brenner DA: Recent advancement
of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat
Sci. 22:512–518. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shan L, Liu Z, Ci L, Shuai C, Lv X and Li
J: Research progress on the anti-hepatic fibrosis action and
mechanism of natural products. Int Immunopharmacol. 75:1057652019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Z, Qin H, Jiang B, Chen W, Cao W,
Zhao X, Yuan H, Qi W, Zhuo D and Guo H: miR-30e-5p suppresses cell
proliferation and migration in bladder cancer through regulating
metadherin. J Cell Biochem. 120:15924–15932. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sarkar D: AEG-1/MTDH/LYRIC in liver
cancer. Adv Cancer Res. 120:193–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li WF, Dai H, Ou Q, Zuo GQ and Liu CA:
Overexpression of microRNA-30a-5p inhibits liver cancer cell
proliferation and induces apoptosis by targeting MTDH/PTEN/AKT
pathway. Tumor Biol. 37:5885–5895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li WF, Ou Q, Dai H and Liu CA:
Lentiviral-Mediated short hairpin RNA knockdown of MTDH inhibits
cell growth and induces apoptosis by regulating the PTEN/AKT
pathway in hepatocellular carcinoma. Int J Mol Sci. 16:19419–19432.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang X, Li W, Tan M, Guo P, Liu X, Pan X,
Yu D, Pang Y, Li D, Wang Q, et al: Identification of miRNAs
involved in liver injury induced by chronic exposure to cadmium.
Toxicology. 469:1531332022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ashmawy AM, Elgeshy KM, Abdel Salam ET,
Ghareeb M, Kobaisi MH, Amin HAA, Sharawy SK and Abdel Wahab AHA:
Crosstalk between liver-related microRNAs and Wnt/β-catenin pathway
in hepatocellular carcinoma patients. Arab J Gastroenterol.
18:144–150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feng GX, Li J, Yang Z, Zhang SQ, Liu YX,
Zhang WY, Ye LH and Zhang XD: Hepatitis B virus X protein promotes
the development of liver fibrosis and hepatoma through
downregulation of miR-30e targeting P4HA2 mRNA. Oncogene.
36:6895–6905. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang N, Ge J, Xiu L, Zhao Z, Duan X, Tian
L, Xie J, Yang L and Li L: HuR mediates motility of human bone
marrow-derived mesenchymal stem cells triggered by sphingosine
1-phosphate in liver fibrosis. J Mol Med (Berl). 95:69–82. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang CW, Hsu HY, Chang HY, Lee YZ and Lee
SJ: ‘Natural cardenolides suppress coronaviral replication by
downregulating JAK1 via a Na+/K+-ATPase
independent proteolysis’. Biochem Pharmacol. 180:1141222020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morbach H, Schickel JN, Cunningham-Rundles
C, Conley ME, Reisli I, Franco JL and Meffre E: CD19 controls
Toll-like receptor 9 responses in human B cells. J Allergy Clin
Immunol. 137:889–898.e6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Molinaro A, Becattini B, Mazzoli A, Bleve
A, Radici L, Maxvall I, Sopasakis VR, Molinaro A, Bäckhed F and
Solinas G: Insulin-Driven PI3K-AKT signaling in the hepatocyte is
mediated by redundant PI3Kα and PI3Kβ activities and is promoted by
RAS. Cell Metab. 29:1400–1409.e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shariati M and Meric-Bernstam F: Targeting
AKT for cancer therapy. Expert Opin Investig Drugs. 28:977–988.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jamal SME, Alamodi A, Wahl RU, Grada Z,
Shareef MA, Hassan SY, Murad F, Hassan SL, Santourlidis S, Gomez
CR, et al: Melanoma stem cell maintenance and chemo-resistance are
mediated by CD133 signal to PI3K-dependent pathways. Oncogene.
39:5468–5478. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Patel KR and Patel HD: p53: An attractive
therapeutic target for cancer. Curr Med Chem. 27:3706–3734. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chao CCK: Mechanisms of p53 degradation.
Clin Chim Acta. 438:139–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
